Spots Global Cancer Trial Database for Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.
Official Title: A Multicenter Randomized Phase II Study Evaluating Tolerance and Efficacy of Capecitabine 5/7 Days With Weekly Paclitaxel Versus the Recommended Treatment Plan of Weekly Paclitaxel-capecitabine, in Patients With Metastatic Breast Cancer.
Study ID: NCT00270491
Study Description
Brief Summary: Tolerance and efficacy of administration of capecitabine 5 out of 7 days associated with weekly paclitaxel compared to the recommended treatment plan of weekly paclitaxel - capecitabine, in patients with metastatic breast cancer.
Detailed Description: The purpose of this study is to know if we can optimize in term of tolerance even of efficacy the plan of administration of weekly paclitaxel associated with capecitabine.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Hôpital HOTEL DIEU, Paris, , France
Contact Details
Name: Rémy LARGILLIER, Physician
Affiliation: Centre ANTOINE LACASSAGNE - NICE (FRANCE)
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
